Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — Investor Presentation (September 2024)
26 slides from Aethlon Medical's investor presentation, September 2024
Slide 1: Corporate Presentation September 2024
Corporate Presentation September 2024 Nasdaq: AEMD wwwˌAethlonMedicalˌcom
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This investor presentation contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
Slide 3: Investment Highlights
Investment Highlights • Developing novel, patented Aethlon Hemopurifier® blood purification device • Early clinical trials have demonstrated virus and EV* clearance both in vitro and in patients • Two FDA “Breakthrough Device” designations • The treatment of individuals with advanced or metastatic c
Slide 4: The Aethlon Hemopurifier
The Aethlon Hemopurifier® FDA Designated “Breakthrough Device” In Viral And Oncology Indications • Safely administered in 164 Hemopurifier sessions in 38 patients1 • Proprietary, patented technology • Has demonstrated clearance of life- threatening viruses • Designed to clear tumor-derived EVs, and
Slide 5: Unique Mechanism of Action
The Hemopurifier®’s Unique Mechanism of Action Captures Virus and Exosomes from a Patient’s Blood via an Extracorporeal Circuit Captures enveloped viral pathogens and exosomes in circulating blood • Hollow-fiber plasma separator filled with proprietary “affinity resin” [Figures B, C] • Size restrict
Slide 6: Pipeline Targeting Multiple Indications
Pipeline Targeting Multiple Indications Early Feasibility Indication Pre-Clinical Study Open for enrollment in Australia. Oncology Solid Tumors Expected enrollment in India by failing anti- end of 2024. PD-1 India COVID-19 Ongoing Viral Infections Completed HCV HIV Single patient case study, Complet
Slide 7: Oncology
a , Oncology
Slide 8: Rationale For Removing Tumor-Derived EVs
The Rationale Exists For The Removal Of Tumor-derived Extracellular Vesicles By Aethlon’s Hemopurifier® To Treat Cancer EVs are small membrane-bound particles that serve as key mediators of cell-cell communication. They carry lipids, proteins, and nucleic acids, and are released by most cell types,
Slide 9: In Vitro Removal Of Cancer-Derived EVs
In Vitro Removal Of Cancer-Derived EVs Has Been Demonstrated 1 • Tumor derived EVs were isolated from cancer patient plasma from multiple tumor types and suspended in buffer • Samples were circulated over a scaled-down version of the Hemopurifier® • The scaled down Hemopurifier was effective for cle
Slide 10: Demonstrated In Vivo Removal Of Exosomes
Demonstrated In Vivo Removal of Exosomes And Noxious microRNAs by the Hemopurifier1 in a COVID-19 Patient Total EV’s and Exosomal2 miRNA over time: Exosomes and miR-424 Exosomes and miR-16 Normalized Exosome miRNA/ml Plasma Normalized Exosome miRNA/ml plasma 0.6 1.4E+12 0.14 1.4E+12 0.5 1.2E+12 0.12
Slide 11: Oncology Clinical Trial Initiation Underway
Hemopurifier Oncology Clinical Trial Initiation Underway • Safety, feasibility and “dose finding” clinical trial in patients with stable or progressive malignancies following a 2-month run-in period of anti-PD-1 antibodies (Keytruda, Opdivo) • Similarly designed trials will take place Australia and
Slide 12: Virology
Virology 12
Slide 13: Early Treatment Option For Bioattacks
The Aethlon Hemopurifier® is Uniquely Positioned as an Early Treatment Option for Future Bioattacks or Pandemic Threats • We believe that the next bioattack or pandemic may occur with an enveloped virus • Enveloped viruses contain mannose structures that are the target for the Affinity Resin in the
Slide 14: In Vitro Removal Of Many Enveloped Viruses
In Vitro Removal of Many Enveloped Viruses Detection Means % Removal at % Removal at Time for 50% Viral Virus Family Virus (medium) Collaborator 1 hr 6 hrs Removal (hrs) Infectivity Assays PCR EboVZ wt (culture) 44 78 (5 h) 1.5 X CDC EboVZmut (culture) 42 79 (4 h) 1.5 X Filoviridae Ebola (culture) 2
Slide 15: Removal Of SARS-CoV-2 Variants
In Vitro Removal of Clinically Relevant SARS-CoV-2 Variants by an Affinity Resin Bearing GNA Has Been Demonstrated 1 Seven SARS-CoV2 variants (104 PFU/mL) in Phosphate Buffered Saline (PBS) buffer passed 3X over column of GNA affinity resin (1g) Table 2. Average Column Capture Efficiency for SARS-
Slide 16: Clinical Experience And Safety Database
Clinical Experience/Safety Database with Aethlon Hemopurifier in Virology Site Indication # of patients # of HP treatments Apollo HCV 4 24 Fortis HCV 6 27 Sigma HIV 1 12 Medicity HCV 10 30 DaVita HCV 9 49 University Hospital Frankfurt Ebola (Emergency Use) 1 1 Hoag Newport Beach COVID-19 (Emergency
Slide 17: Evidence Of SARS-CoV-2 Capture And Clearance
Evidence of SARS-CoV-2 Capture and Clearance by Hemopurifier®1 • 67yo male with multiple organ system dysfunction due to documented SARS-CoV-2 infection despite all standard therapies VIRAL COPIES NORMALIZED TO RNase P • Patient underwent 6-hour 15 minute Hemopurifier session between Plasma (0645-13
Slide 18: COVID-19 India Trial Update
COVID-19 India Trial Update: Treatment Of SARS-CoV-2 Infection In Humans With Hemopurifier® Device • Regulatory agency in India approved the use of Hemopurifier® devices for clinical trial use • Studying ICU patients with severe or life-threatening disease • Designed to include up to 15 patients at
Slide 19: Pre-Clinical: Renal Transplantation
Pre-Clinical: Renal Transplantation 19
Slide 20: Potential Role In Renal Transplantation
Rationale for Potential Role of Hemopurifier in Renal Transplantation • Renal Transplantation is the goal standard treatment for end-stage renal disease • Significant shortage of available donor kidneys as well 25% discard rate of recovered kidneys1 • Ischemia Reperfusion injury leads to delayed gra
Slide 21: In Vitro Kidney Transplantation Data
In Vitro Data Highlights the Hemopurifier’s® Potential in Kidney Transplantation The Aethlon Hemopurifier significantly depletes EVs and DNA-associated EVs from renal perfusates The Aethlon Hemopurifier significantly depletes microRNAs from renal perfusates Probe Name Accession # 24P vs. ctrl FDR (p
Slide 22: Pre-Clinical Renal Transplantation Conclusions
Pre-Clinical Renal Transplantation Activities- Conclusions • Large amounts of extracellular vesicles (EVs) and microRNAs are released from recovered organs during machine perfusion • The Aethlon Hemopurifier was capable of removal of EVs, double stranded DNA associated with EVs and microRNAs that ha
Slide 23: Patent Portfolio Protection
Aethlon’s patent portfolio provides protection until as early as 2025 (issued patents) and as late as 2044 (if pending applications are granted) United States International • Issued Patents: • Issued Patents: • 3 US patents issued covering extracorporeal removal of • 24 foreign patents covering exos
Slide 24: Senior Management Team
Senior Management Team Has Extensive Experience With Both Medical Devices And Therapeutics James B. Frakes, MBA, Interim CEO & Chief Financial Officer • Over 30 years public company CFO experience • Investment banking & venture capital Guy Cipriani, MBA, Chief Operating Officer • 20 years transactio
Slide 25: Key Financial Highlights
Key Financial Highlights • Approximately $9.1 million in cash as of June 30, 2024 • No debt on balance sheet • Approximately 13.9 million shares outstanding as of September 13, 2024 • Market capitalization of $5.4 million as of September 13, 2024 • Trading on Nasdaq Capital Market under the ticker “
Slide 26: Contact Information
Contact Information 11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 619.941.0360 Nasdaq: AEMD wwwˌAethlonMedicalˌcom This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including: whether and when our prod
Aethlon Medical — Investor Presentation (September 2024) on 6ix